Moderna Announces Supply Agreement with the Ministry of Public Health to Supply Qatar with mRNA Vaccine Against COVID-19 (mRNA-1273)

Moderna Announces Supply Agreement with the Ministry of Public Health to Supply Qatar with

mRNA Vaccine Against COVID-19 (mRNA-1273)

October 26, 2020

Supply agreement reflects Moderna’s commitment to make its vaccine available in Qatar

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 26, 2020-- Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA

(mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced a supply agreement with the

Ministry of Public Health of Qatar for mRNA-1273, Moderna’s vaccine candidate against COVID-19, to support the Ministry’s ongoing efforts to secure

early access to a safe and effective COVID-19 vaccine for the people of Qatar.

“We appreciate the confidence of the Ministry of Health of Qatar in our mRNA vaccine platform and the collaboration we have had to date,” said

Stéphane Bancel, Moderna’s Chief Executive Officer. “We are advancing the clinical development of mRNA-1273 with our Phase 3 COVE study, which

is now fully enrolled with a representative demography of participants across ages, ethnicities and high-risk populations. In parallel we are scaling up

our manufacturing capability with our strategic partners, Lonza and Rovi, to address this global health emergency by delivering a safe and effective

vaccine to the people of Qatar and around the world.”

The Phase 1 interim analysis showed that mRNA-1273 was generally well-tolerated across all age groups and induced rapid and strong immune

responses against SARS-CoV-2. mRNA-1273 is currently being studied in a Phase 3 randomized, 1:1 placebo-controlled trial of 30,000 participants at

the 100 μg dose level in the U.S. On Thursday, October 22, Moderna completed enrollment of the Phase 3 COVE study. For more information about

the COVE study, click here. mRNA-1273 currently is not approved for use by any regulatory body.

Moderna is scaling up global manufacturing to be able to deliver approximately 500 million doses per year and possibly up to 1 billion doses per year,

beginning in 2021.

Over the past nine years, Moderna has invested in creating and developing a novel platform for designing and manufacturing a new class of

mRNA-based vaccines. The investments in this proprietary platform have enabled Moderna to expeditiously create, manufacture and clinically

develop mRNA-1273 to potentially address the current COVID-19 pandemic.

About Moderna

Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. mRNA medicines are

designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that can have a therapeutic or preventive benefit and have

the potential to address a broad spectrum of diseases. The company’s platform builds on continuous advances in basic and applied mRNA science,

delivery technology and manufacturing, providing Moderna the capability to pursue in parallel a robust pipeline of new development candidates.

Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and cardiovascular diseases,

independently and with strategic collaborators.

Headquartered in Cambridge, Mass., Moderna currently has strategic alliances for development programs with AstraZeneca PLC and Merck & Co.,

Inc., as well as the Defense Advanced Research Projects Agency (DARPA), an agency of the U.S. Department of Defense, and the Biomedical

Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR)

within the U.S. Department of Health and Human Services (HHS). Moderna has been named a top biopharmaceutical employer by Science for the

past five years. To learn more, visit www.modernatx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended,

including statements regarding: the Company’s development of a potential vaccine against the novel coronavirus (mRNA-1273), the potential for

mRNA-1273 to prevent COVID-19 disease and slow the spread of SARS-CoV-2, the terms of the Company’s supply of mRNA-1273 to the Ministry of

Public Health of Qatar, and the timing for the manufacturing, supply and distribution of mRNA-1273. In some cases, forward-looking statements can be

identified by terminology such as “will,” “may,” “should,” “could,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,”

“potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these

words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these

forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s

control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks,

uncertainties, and other factors include, among others: preclinical and clinical development is lengthy and uncertain, especially for a new class of

medicines such as mRNA, and therefore our preclinical programs or development candidates may be delayed, terminated, or may never advance to or

in the clinic; no commercial product using mRNA technology has been approved and may never be approved; mRNA drug development has

substantial clinical development and regulatory risks due to the novel and unprecedented nature of this new class of medicines; despite having

ongoing interactions with the FDA or other regulatory agencies, the FDA or such other regulatory agencies may not agree with the Company’s

regulatory approval strategies, components of our filings, such as clinical trial designs, conduct and methodologies, or the sufficiency of data

submitted; the fact that the rapid response technology in use by Moderna is still being developed and implemented; potential adverse impacts due to

the global COVID-19 pandemic such as delays in clinical trials, preclinical work, overall operations, regulatory review, manufacturing and supply chain

interruptions, adverse effects on healthcare systems and disruption of the global economy; and those risks and uncertainties described under the

heading “Risk Factors” in Moderna’s most recent Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (SEC) and

in subsequent filings made by Moderna with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna

disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new

information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of

the date hereof.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201026005485/en/

Moderna Contacts

Media:

Colleen Hussey

Director, Corporate Communications

617-335-1374

Colleen.Hussey@modernatx.com

Investors:

Lavina Talukdar

Head of Investor Relations

617-209-5834

Lavina.Talukdar@modernatx.com